Clinician scientist at @vallhebron Phase 1 and Cancer Genomics Group @VHIO. Former med onc fellow at @pmcancercentre, Phase1/Head and Neck, biomarkers.
Thank you @myESMO for highlighting our recent publication in @eClinicalMed unveiling dowstream effects of performing #NGS in pts with advanced solid tumors enrolled in OCTANE. Very nice summary!
👇
https://t.co/MMu8S2Bl0e
👇
https://t.co/7JNk2C3lmF
🇪🇺 @piris_alejandro and Alberto Hernando Calvo represented #VHIO at the European Parliament, invited by @CGIclinics in recognition of VHIO’s contribution to #JAPCM and its pilot project within the Supranational Molecular Tumor Board initiative. 🔬💡
@EU_Health
Happening now at TAT 2026 @myESMO . Parp inh and synthetic lethality🧬Great presentations by Victoria Rodriguez and Xavi Maldonado from @vallhebron@VHIO
🚀 We took part in the kick-off meeting of the Joint Action on Personalised Cancer Medicine (JA PCM), a new EU initiative to expand access to personalised cancer care across Europe.
🔬 As partners, we lead a pilot to create a supranational Molecular Tumor Board for rare and complex cases and work on harmonising data collection.
🌎 Together, advancing personalised cancer medicine.
Thanks for the mention @CataniGreta! A true pleasure working with you under the expert guidance of @AhernandoCalvo and the rest of the @VHIO team. Thrilled to share our review on biomarkers in early-phase immunotherapy trials!
Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn
Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible
https://t.co/ca26OBMdy7
Happy to see this finally out! Humbled by the support from my former mentors at @pmcancercentre and Marc Oliva at @ICO_oncologia. An international collaboration including ultra-rare sinonasal cancers.
📌Now that we understand the prognostic factors, let's find druggable targets
@drenriquegrande !! 11 años avanzando en la oncología de precisión y aplicando la genómica al día a día! Un lujo contar con un panel de ponentes brutal !! Pero dejad que me 🤤 con mis amigos del @VHIO que se han salido como siempre! @rdienstmann@JHernando3@AhernandoCalvo 🙌🏼👏🏼
📍Happy to share this publication @JCOPO_ASCO validating VIGex signature in the INSPIRE trial. Improved predictive performance for IO benefit was observed with VIGex+ctDNA dynamics in this international collaboration 🇨🇦 🇪🇸@pmcancercentre@VHIO@vallhebron https://t.co/BUSUtR9AY6
Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in pts with pMMR CRC or pancreatic cancer at @pmcancercentre. Mentorship from Aaron Hansen and @lillian_siu and support from @PughLab@bhaibeka labs @OICR_news and others!
https://t.co/0PDKCte0Nu
@cabify_espana Taxi reservado con anterioridad en Barcelona para las 7:10. Mensaje de conductor en camino llegada en 49 minutos (a las 6:50). El mismo conductor que habia aceptado mi reserva esta en curso de otro trayecto sabiendo que llegará tarde. Segunda vez en el mismo mes.
Missed yesterday's session?
👉 Stay up to date with innovative #immunotherapy approaches and engage with the panel of expert presenters by submitting your questions live. #ESMOVirtualPlenary
🔗 https://t.co/C10evb5Nkp
#ESMOVirtualPlenary: Safety & efficacy of a PD-1/IL-2 bispecific antibody fusion protein show proof-of-concept on its capacity to overcome resistance to #immunotherapy in pre-treated pts & some populations w/ poor prognosis.
#ESMODailyReporter
👉 https://t.co/GoHFhUXgZm
Almost starting #ASCO24, and receiving the news that our review in new therapies (ADC, BsAbs) for H&N SCC and nasopharyngeal carcinoma is finally published in Cancer Treatment Reviews! Congrats to all co-authors! 👏#HNCSM@royalmarsdenNHS@VHIO
https://t.co/bjqsBfX689